NCT03874325 - Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2019

Primary Completion Date

November 15, 2020

Study Completion Date

January 6, 2021

Conditions

Breast CancerHormone Receptor Positive Tumor

Interventions

DRUG

Durvalumab

1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.

DRUG

Anastrozole 1mg

Participants will self administer 1 mg anastrozole by mouth daily for 6 months.

DRUG

Letrozole 2.5mg

Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.

DRUG

Exemestane 25 MG

Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.

Trial Locations (1)

H. Lee Moffitt Cancer Center and Research Institute, Tampa